FDA Approves Airsupra Asthma Rescue Inhaler
AstraZeneca's Airsupra is the first FDA-approved combination of an inhaled corticosteroid and a short-acting beta-agonist for prevention of asthma exacerbations.
AstraZeneca's Airsupra is the first FDA-approved combination of an inhaled corticosteroid and a short-acting beta-agonist for prevention of asthma exacerbations.
The FDA approved AstraZeneca and Amgen's medication, Tezspire, to treat severe asthma for patients aged 12 years and older.
A Data & Safety Monitoring Board expressed concern that AstraZeneca may have included outdated information in a Phase 3 trial for its COVID-19 vaccine.
Breztri Aerosphere is a single-inhaler, fixed dose triple-combination of the ICS budesonide, the LAMA glycopyrrolate, and LABA formoterol fumarate.
Read MoreThe COVID-19 vaccine being developed by Oxford University and AstraZeneca led to an immune response in roughly 1,000 patients, early study results show.
Read MoreData from a late-stage trial on the cancer drug Imfinzi, in combination with chemotherapies, demonstrated improvement in survival of certain lung cancer patients, AstraZeneca Plc announced this week.
Read MoreNew data demonstrated that the maintenance combination asthma therapy, Symbicort (budesonide/formoterol fumarate dehydrate), provides a rapid, clinically significant bronchodilatory response.
Read More